CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, ...
* XERIS PHARMACEUTICALS - $0 COPAY CARD IS AVAILABLE TO COMMERCIALLY INSURED PATIENTS, WHO MAY OR MAY NOT HAVE GVOKE PFS COVERED BY THEIR INSURANCE PLAN Source text for Eikon: Further company coverage ...
Credit: Getty Images. The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older. The Food and Drug Administration ...
First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback